← Peptide researchRESEARCH FAMILIES / UPDATED OCTOBER 2026

Russian peptide design programs

Russian programs that designed peptides to mimic neurotrophins, modified short glycine–proline sequences or studied marine peptides that act on ion channels.

Findings from selected studies

  • Dilept compared with risperidone

    In a 25-person psychiatric comparison, the WAIS-R coding task favored Dilept by 1.90 points. The negative-symptom score showed no significant advantage over risperidone.

Browse study findings by subject ↓

Educational information only. Not medical advice. Seek qualified healthcare help for any medical condition. Most new records concern cells, animals, patents or early human studies; they are not treatment recommendations.

Closely related analogues share one card where that makes comparison clearer. Each family page separates its members, source types and findings. Code names in a patent are not a catalogue of proven therapies.

Three ways into short-peptide research

Reproduce part of a protein

NGF, BDNF, NT-3 and NT-4 mimetics test whether selected structural loops can reproduce particular signaling responses. Even small structural changes can alter the measured biological effect.

GK-2 versus GK-6 primary study ↗

Trace an active fragment

Myelopeptides and glyprolins connect tissue fractions with defined sequences. Detecting a peptide, proposing its protein origin and demonstrating a physiological function are separate questions.

MP-4 isolation and cell research ↗

Start from a drug’s structure

The Zakusov developers describe piracetam-inspired Noopept and sulpiride-inspired Dilept as a distinct approach. Their historical account belongs alongside the original experiments, not in place of them.

Developer design account ↗

Ion-channel peptide research

These peptides act on different channels and can have opposite effects. Ms13-1 is a pain-provoking research probe; it should not be grouped with protective findings. M2IP is an international comparator.

Targets and experimental findings
PeptideTargetResearch context
APHC peptidesTRPV1Channel modulation; experimental pain research
Ueq 12-1TRPA1A separate sea-anemone TRPA1 ligand
HCIQ2c1TRPA1Open-state stabilization and restricted hyperactivation; mouse pain and inflammation findings
Hcr ASIC peptidesASIC1aInhibitory peptide research
Ms13-1ASIC1aPositive modulation; induced pain-related behavior in mice
M2IPTRPM2International comparator; inhibition and mouse ischemic-injury findings

Channel assays and animal experiments do not establish clinical effectiveness or safety. Each profile links the relevant source and its review scope.

Explore the families

FAMILY RECORD

NGF mimetics: GK & GTS series ↗

Миметики ФРН

A family of experimental peptides designed from exposed loops of nerve growth factor. Related structures can differ in cell survival, differentiation and pain responses.

No human treatment trial assessed for this family

FAMILY RECORD

BDNF mimetics: GSB, GBK & GTS ↗

Миметики BDNF

Small experimental mimetics of different BDNF loops, grouped for comparison of chemistry, signaling and behavioral results.

No human treatment trial assessed for this family

FAMILY RECORD

NT-3 mimetics: GTS-301 & GTS-302 ↗

ГТС-301 / ГТС-302

A paired NT-3 research record comparing two loop-4 mimetics with different downstream signaling and animal pharmacology.

No human treatment trial assessed for this family

PEPTIDE RECORD

GZS-411 ↗

ГЗС-411

A 2026 experimental dimeric dipeptide designed from NT-4 loop 1. Its currently linked findings are cell-based.

No human treatment trial assessed for this family

FAMILY RECORD

CPG & GZK-111 ↗

ЦПГ / ГЗК-111

A grouped record for endogenous cyclo(Pro-Gly), its experimental linear precursor GZK-111 and the connection to Noopept metabolism.

No human treatment trial assessed for this family

FAMILY RECORD

Glyprolins & PGP hybrids ↗

Глипролины

A family record separating simple Pro/Gly peptides, PGP-containing hybrids and proposed protein-fragment lineages.

No human treatment trial assessed for this family

FAMILY RECORD

Myelopid & MP-1–MP-6 ↗

Миелопид / миелопептиды

A marrow-peptide family separating the original mixture from defined isolates and later synthetic research. Each member needs its own evidence.

No human treatment trial assessed for this family

FAMILY RECORD

Sedatin & dermorphin analogues ↗

Седатин / аналоги дерморфина

A family of synthetic dermorphin-related peptides studied in tissue homeostasis, oxidative injury and opioid pharmacology.

No human treatment trial assessed for this family

FAMILY RECORD

NALE & peptide G ↗

НАЛЭ

An experimental non-opiate leu-enkephalin analogue used to investigate cytoprotection apart from conventional opioid effects.

No human treatment trial assessed for this family

FAMILY RECORD

GB-115 & CCK analogues ↗

ГБ-115

A synthetic CCK-4-related dipeptide derivative studied as Ranquilon in randomized human anxiety trials; related CCK-4 and stereochemical compounds are kept distinct.

Phase II (168), phase III (220), active-comparator phase IV (200), and earlier pilot reports

FAMILY RECORD

Liberol / TRH research ↗

Либерол

An archival occupational-research record for the Liberol/TRH branch, covering historical human functional-reserve experiments.

Human dissertation material; original scan and study design pending

FAMILY RECORD

Bestim ↗

Бестим

A gamma-linked D-Glu/L-Trp dipeptide with immune-cell binding research and limited human adjunct-treatment reports. Distinct from Thymogen and Thymodepressin.

Human adjunct-treatment reports linked; allocation and independent effects remain uncertain

FAMILY RECORD

Imunofan ↗

Имунофан

A synthetic RDKVYR hexapeptide with cell, animal and human wound-related research. Historical Thymohexin names have conflicting sequence order.

A 69-patient diabetic-foot trial and a 28-patient ulcer report are linked; full appraisal remains pending

FAMILY RECORD

Gepon & ezrin-derived peptides ↗

Гепон

An ezrin-related peptide family with a patent identity trail, an uncontrolled human ulcerative-colitis report and preclinical experiments. Related fragments are separate research objects.

Uncontrolled 36-patient ulcerative-colitis report linked; no controlled benefit established

RELATED RECORDS / NEW EVIDENCE

What changes in the existing map?

The CPG and GZK-111 profile now connects AMPA/TrkB work, IGF-1 experiments, rat metabolism, coagulation assays and the human stroke biomarker cohort. The 2026 Selank ischemia study remains a separate early gene-expression experiment in rats.

  • Noopept: original CPG-metabolism evidence and the separate GZK-111 precursor program.
  • Dilept: the psychiatric pilot, metabolite GZR-125 and animal withdrawal studies, kept separate from environmental testing.
  • Semax and Selank: glyprolin design history, including a direct experiment showing that short PGP peptides did not reproduce Semax’s expression pattern.
  • Dalargin: separate NALE and Sedatin branches, including the 2026 NOP-blockade follow-up.
  • Thymogen and Thymohexin: Bestim binding and the Imunofan sequence distinction.
OPEN ARCHIVE / NOT VERIFIED FINDINGS

Sources still needed

Occupational adaptation: Cortexin and comparators

Pyatibrat’s 2016 dissertation listing identifies separate Metaprot, Cytoflavin, Cortexin and Gliatilin sections and a pharmacogenetic research program. Original tables and allocation details are still needed before extracting group-specific effect estimates or reconciling reported military cohorts.

Dissertation listing and excerpt ↗

The existing 2007 environmental-chamber report concerns a different study. Dissertation and review summaries should not be counted as independent replication.

These leads remain visible without being presented as established mechanisms, new clinical indications or independent replications.

FMRFamide, FaRPs & peptide mixtures

The 1996 rat resuscitation citation and Krushinskaya’s dissertation on hemorrhage and hypobaric hypoxia identify the research program. The available sources leave exact sequences, mixture composition and experimental results unclear.

Indexed animal-study citation ↗

Dissertation source ↗

Hydra morphogen & CRH fragments

PMH/Hydra head-activator analogues and Pro–Pro–Ile (CRH 2–4) remain acquisition targets. Historical sequence transcriptions and mammalian immunoreactivity require original analytical confirmation.

Cryptides and neighboring programs

MP-2/hemorphin relationships, spinorphin/tynorphin, GPE and hydroxyproline peptides need sequence-specific primary records. A common fragment motif alone does not establish origin, receptor action or clinical benefit.

Unresolved analogue libraries

A10/A17/A43 now have a transcribed sequence table, but the original scan remains needed. GB-101, GBK-108/201 and GK-2f need complete member-specific assay mapping. The 2026 NT-3 stroke citation, Myelopeptides monograph and proposed extended NT-4 library also require further recovery.

Other immune-peptide lineages

Likopid/GMDP and the historical Blastolysin trail are separate bacterial cell-wall research, not evidence for thymic or marrow peptides. Deltaran formulation research should remain under the existing DSIP record.

DSIP and formulation distinctions ↗

Bibliography & source documents ↗

How Molekul assesses evidence ↗

Study findings by subject

80 source records

2024 · Animal research

Low-Molecular Neurotrophin-3 Mimetics with Different Patterns of Postreceptor Signaling Activation Attenuate Differentially Morphine Withdrawal in Rats.

GTS-301 and GTS-302 reduced withdrawal signs in morphine-dependent rats; only GTS-302 reduced withdrawal-associated mechanical allodynia. Cell assays reported different downstream signaling, with AKT/mTOR recruitment for GTS-302. The publisher’s 2025 erratum corrects an author’s surname, not experimental results.

Methods and source ↗ · NT-3 mimetics: GTS-301 & GTS-302

2026 · Animal research

Spinorphin Ameliorates Nitroglycerin-Induced Migraine-Like Responses and Trigeminovascular Neuroinflammation Potentially Through Opioid Receptor-Mediated Mechanisms

Spinorphin reduced mechanical hypersensitivity, c-Fos, CGRP and meningeal mast-cell degranulation in a rat migraine model. Nalmefene attenuated these effects. In ex vivo preparations, Spinorphin reduced capsaicin-evoked CGRP release and enhanced sumatriptan’s inhibitory effect on that endpoint.

Methods and source ↗ · Myelopid & MP-1–MP-6

2026 · Animal research

Spinorphin Attenuates Acute Experimental Seizures and Associated Neurochemical Alterations: Possible Involvement of Opioid Receptors

Spinorphin reduced behavioral seizures and cortical epileptiform spike frequency, improved passive-avoidance retention, and altered glutamate, GABA and inflammatory/oxidative markers. Nalmefene substantially attenuated the effects but did not fully reverse them, suggesting both opioid-related and other mechanisms.

Methods and source ↗ · Myelopid & MP-1–MP-6

1999 · Lab research

Activity profiles of dalargin and its analogues in μ-, δ- and κ-opioid receptor selective bioassays

Isolated-tissue assays showed that D-Ala configuration and other sequence modifications altered potency, peptidase resistance and receptor preference. The tested Dalargin profile favored μ activity; this does not settle receptor contributions in every tissue or disease model.

[L-Ala²] analogue · 19-fold less potent; δ/μ activity ratio 6.78; naloxone KB 7.9 nM

Methods and source ↗ · Dalargin

2000 · Animal research

Dalargin and liver function during acute hypoxia

The dissertation transcription reports longer survival in severe hypobaric hypoxia at testing times through 168 hours after ordinary intravenous administration and through 336 hours with erythrocyte-carrier delivery. Liver and oxidative-stress markers varied by delivery method and time.

Methods and source ↗ · Dalargin

2023 · Comparison in people

Dalargin and oxidative stress in severe combined trauma: a prospective clinical study

Among 104 patients (38 Dalargin, 66 controls), the authors reported lower oxidative-stress markers and fewer ARDS/acute kidney injury events. Mortality and infectious complications were comparable; antioxidant activity remained below normal. Hospitalization was shorter among survivors receiving Dalargin.

Mortality · 8/38 (21.1%) versus 17/66 (25.8%) · p=0.6412; nonsignificant

Methods and source ↗ · Dalargin

2026 · Comparison in people

Changes in retinal light sensitivity and morphometry during surgical treatment of primary glaucoma with physiotherapeutic stimulation

After glaucoma surgery, a physiotherapy package including Semax electrophoresis improved visual-field mean deviation from −8.62 ± 1.86 to −4.33 ± 0.98 dB, with benefit maintained through six months. The comparison group received Semax nasal drops and returned to baseline by month three. Structural retinal measures and visual-field index did not differ significantly.

Visual-field mean deviation · −8.62 ± 1.86 → −7.03 ± 1.36 → −4.33 ± 0.98 dB · Baseline → after surgery → after added physiotherapy · p<0.01 after surgery; p<0.0001 after physiotherapy

Methods and source ↗ · Semax

2025 · Lab research

Semax and ACTH(6–9)PGP in human microglial and neuronal cell cultures

After seven hours, Semax and ACTH(6–9)PGP each reduced IL-1β and IL-6 in LPS-stimulated HMC-3 cultures. The report gives the size of the LPS response and the direction of the peptide effects.

IL-1β and IL-6 in HMC-3 cultures · LPS alone raised IL-1β to 1.5× and IL-6 to 2.0× unstimulated levels. Each peptide lowered both cytokines versus LPS alone. · 7 hours · The authors report significant reductions with peptide treatment. Exact effect sizes and p-values are absent from the summary.

Methods and source ↗ · Semax

2026 · Comparison in people

[Effect of a combined physiotherapeutic approach on changes in functional parameters after endovitreal surgery of rhegmatogenous retinal detachment with a favorable anatomical outcome].

The combined heliox and Semax electrophoresis group showed greater recovery of visual acuity and retinal sensitivity than the Semax nasal-drop group.

Combined treatment · Heliox: 21% oxygen, 79% helium · After 15 minutes, 1% Semax electrophoresis for 10 minutes; eight daily procedures starting postoperative day 5

Methods and source ↗ · Semax